These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 21700758)
1. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Oh IY; Park KW; Kang SH; Park JJ; Na SH; Kang HJ; Koo BK; Jeong YH; Hwang JY; Kwak CH; Park Y; Hwang SJ; Ko YG; Shin DJ; Jang Y; Kim HS Heart; 2012 Jan; 98(2):139-44. PubMed ID: 21700758 [TBL] [Abstract][Full Text] [Related]
2. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617 [TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880 [TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659 [TBL] [Abstract][Full Text] [Related]
6. Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. Park KW; Park JJ; Lee SP; Oh IY; Suh JW; Yang HM; Lee HY; Kang HJ; Cho YS; Koo BK; Youn TJ; Chae IH; Choi DJ; Oh BH; Park YB; Kim HS Heart; 2011 Apr; 97(8):641-7. PubMed ID: 21345843 [TBL] [Abstract][Full Text] [Related]
7. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612 [TBL] [Abstract][Full Text] [Related]
8. Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers. Nishio R; Shinke T; Otake H; Nakagawa M; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Kuroda M; Hirata K Thromb Res; 2013 Nov; 132(5):558-64. PubMed ID: 24080149 [TBL] [Abstract][Full Text] [Related]
10. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Sawada T; Shinke T; Shite J; Honjo T; Haraguchi Y; Nishio R; Shinohara M; Toh R; Ishida T; Kawamori H; Kozuki A; Inoue T; Hariki H; Hirata K Circ J; 2011; 75(1):99-105. PubMed ID: 21099121 [TBL] [Abstract][Full Text] [Related]
11. Cytochrome p-450 polymorphisms and response to clopidogrel. Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084 [TBL] [Abstract][Full Text] [Related]
12. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435 [TBL] [Abstract][Full Text] [Related]
13. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. Kim IS; Jeong YH; Park Y; Park KS; Yun SE; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S JACC Cardiovasc Interv; 2011 Apr; 4(4):381-91. PubMed ID: 21511217 [TBL] [Abstract][Full Text] [Related]
14. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114 [TBL] [Abstract][Full Text] [Related]
15. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Tiroch KA; Sibbing D; Koch W; Roosen-Runge T; Mehilli J; Schömig A; Kastrati A Am Heart J; 2010 Sep; 160(3):506-12. PubMed ID: 20826260 [TBL] [Abstract][Full Text] [Related]
16. [Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention]. Tang XF; He C; Yuan JQ; Meng XM; Yang YJ; Qin XW; Qiao SB; Liu HB; Wu YJ; Yao M; Chen J; You SJ; Wu Y; Li JJ; Dai J; Chen JL; Gao RL; Chen ZJ Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jul; 39(7):617-20. PubMed ID: 22088240 [TBL] [Abstract][Full Text] [Related]
17. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. Lee JM; Park S; Shin DJ; Choi D; Shim CY; Ko YG; Kim JS; Shin ES; Chang CW; Lee JE; Jang Y Am J Cardiol; 2009 Jul; 104(1):46-51. PubMed ID: 19576320 [TBL] [Abstract][Full Text] [Related]
18. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445 [TBL] [Abstract][Full Text] [Related]
19. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. Hochholzer W; Trenk D; Fromm MF; Valina CM; Stratz C; Bestehorn HP; Büttner HJ; Neumann FJ J Am Coll Cardiol; 2010 Jun; 55(22):2427-34. PubMed ID: 20510210 [TBL] [Abstract][Full Text] [Related]
20. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]